57115-24-9 Usage
Uses
Used in Pharmaceutical Industry:
3-oxo-2-phenylbutanenitrile is used as an intermediate for the synthesis of various pharmaceuticals and organic compounds. Its versatile structure allows for the production of a wide range of molecules, making it an important building block in this industry.
Used in Fragrance Industry:
3-oxo-2-phenylbutanenitrile is used as a precursor for the synthesis of fragrances and other fine chemicals. Its unique structure contributes to the creation of various scent compounds.
Used in Asymmetric Synthesis:
3-oxo-2-phenylbutanenitrile has been studied for its potential use as a chiral auxiliary in asymmetric synthesis reactions. This application is significant in the development of enantiomerically pure compounds, which are crucial in various chemical and pharmaceutical processes.
However, it is important to handle 3-oxo-2-phenylbutanenitrile with care as it is toxic and can cause skin and eye irritation. Overall, 3-oxo-2-phenylbutanenitrile is an important and versatile chemical building block with various applications in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 57115-24-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,1,1 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 57115-24:
(7*5)+(6*7)+(5*1)+(4*1)+(3*5)+(2*2)+(1*4)=109
109 % 10 = 9
So 57115-24-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O/c1-7(12)8(6-10)9-4-2-3-5-11-9/h2-5,8H,1H3
57115-24-9Relevant academic research and scientific papers
PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
-
Paragraph 506; 507, (2018/01/17)
The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R21, R22, R23, R24 and R25 are as defined herein.
